Fonte: Journal of Cardiothoracic and Vascular Anesthesia. Unidade: FMRP
Assuntos: SISTEMA CARDIOVASCULAR, TÓRAX
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EVORA, Paulo Roberto Barbosa e RODRIGUES, Alfredo José e CELOTTO, Andrea C. "Methylene blue should be relegated to rescue use and not as first-line therapy" cannot become a paradigm. [Carta]. Journal of Cardiothoracic and Vascular Anesthesia. Maryland Heights: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1053/j.jvca.2013.09.009. Acesso em: 16 nov. 2025. , 2014APA
Evora, P. R. B., Rodrigues, A. J., & Celotto, A. C. (2014). "Methylene blue should be relegated to rescue use and not as first-line therapy" cannot become a paradigm. [Carta]. Journal of Cardiothoracic and Vascular Anesthesia. Maryland Heights: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1053/j.jvca.2013.09.009NLM
Evora PRB, Rodrigues AJ, Celotto AC. "Methylene blue should be relegated to rescue use and not as first-line therapy" cannot become a paradigm. [Carta] [Internet]. Journal of Cardiothoracic and Vascular Anesthesia. 2014 ; 28( 2): e11.[citado 2025 nov. 16 ] Available from: https://doi.org/10.1053/j.jvca.2013.09.009Vancouver
Evora PRB, Rodrigues AJ, Celotto AC. "Methylene blue should be relegated to rescue use and not as first-line therapy" cannot become a paradigm. [Carta] [Internet]. Journal of Cardiothoracic and Vascular Anesthesia. 2014 ; 28( 2): e11.[citado 2025 nov. 16 ] Available from: https://doi.org/10.1053/j.jvca.2013.09.009
